Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Gains from Sales and Divestitures (2021 - 2025)

Medicinova (MNOV) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a N/A change, with the full-year FY2025 number at $1.1 million, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $1.1 million for Q4 2025 at Medicinova, up from $970000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.2 million in Q4 2021 to a low of $9000.0 in Q3 2024.
  • A 4-year average of $856033.3 and a median of $970000.0 in 2025 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: tumbled 98.77% in 2024, then skyrocketed 10677.78% in 2025.
  • Medicinova's Gains from Sales and Divestitures stood at $1.2 million in 2021, then plummeted by 38.42% to $730350.0 in 2023, then crashed by 98.77% to $9000.0 in 2024, then surged by 11788.89% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Gains from Sales and Divestitures are $1.1 million (Q4 2025), $970000.0 (Q3 2025), and $970000.0 (Q2 2025).